Biomarkers for Predicting Mortality in Patients With Suspected Sepsis

April 3, 2026 updated by: Antalya Training and Research Hospital

The Use of Biomarkers for Predicting Mortality in Patients With Suspected Sepsis

This retrospective study aimes to analyze the association of a number of routinely performed biomarkers with mortality in patients admitted to ICU with suspected sepsis.

The study includes patients >18 years of age, who had been admitted to the ICU with suspected sepsis. At ICU admission, baseline levels of PCT, CRP, albumin and lactate as well as WBC, neutrophil and lymphocyte counts will recorded.

Study Overview

Status

Completed

Detailed Description

This study aimes to investigate the association of a number of biomarkers with 28-day mortality of patients admitted to the ICU with suspected sepsis, which included C-reactive protein (CRP), procalcitonin (PCT), WBC count, neutrophil count, lymphocyte count, albumin and lactate.

Data will obtained from hospital electronic medical records. Data includes age, sex, duration of ICU stay, origin of infection (urinary, abdominal, pulmonary, soft tissue, central nervous system, catheter-related, mixed, others) and comorbidities (hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic renal failure, heart failure, coronary artery disease, malignancies, others). Whether patients were admitted to the ICU following a scheduled surgery or emergency surgery will also recorded.

At admission, baseline levels of PCT, CRP, albumin and lactate as well as WBC, neutrophil and lymphocyte counts will recorded.

The primary outcome is 28-day mortality. For patients with multiple episodes requiring ICU admission, only the most recent episode will taken into consideration.

Study Type

Observational

Enrollment (Actual)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Niğde Province
      • Niğde, Niğde Province, Turkey (Türkiye), 51200
        • Niğde Ömer Halisdemir University Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population is patients older than 18 years of age who have primary diagnoses of admission to intensive care unit are infection and suspected sepsis.

Description

Inclusion Criteria:

  • >18 years of age
  • admission to the ICU with suspected sepsis

Exclusion Criteria:

  • ICU admission following cardiopulmonary resuscitation or cardiac surgery
  • Having a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
  • Interruption of the treatment process because of transfer to another healthcare facility

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
28-day mortality
Time Frame: 28 days
mortality within 28 days after intensive care admission
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sümeyye Uğur, Antalya Training And Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2023

Primary Completion (Actual)

August 1, 2024

Study Completion (Actual)

August 1, 2024

Study Registration Dates

First Submitted

April 3, 2026

First Submitted That Met QC Criteria

April 3, 2026

First Posted (Actual)

April 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 9, 2026

Last Update Submitted That Met QC Criteria

April 3, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Subscribe